EGFR and ovarian carcinoma: Unfortunately, response to EGFR-targeted tyrosine kinase-based inhibitors (TKIs) in unselected ovarian cancer patient populations has not been encouraging, with 0-6% response rates in patients with persistent or recurrent disease [10-12], and no significant survival benefit as a maintenance therapy for patients with response or stable disease after first-line chemotherapy [13].